Topotarget bullish, Spectrum cautious as belinostat moves ahead for PTCL
This article was originally published in Scrip
Executive Summary
Spectrum Pharmaceuticals has sought to provide some clarity on the histone deacetylase (HDAC) inhibitor belinostat, which is in development with Danish partner Topotarget for the treatment of haematological malignancies and solid tumours, but the update seemed instead to create some confusion.